- Home
- CADL vs LCTX Comparison
CADL vs LCTX Comparison
Compare CADL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CADL | LCTX |
|---|---|---|
| Founded | 1999 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 407.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CADL | LCTX |
|---|---|---|
| Price | $5.67 | $1.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $19.43 | $4.25 |
| AVG Volume (30 Days) | 976.9K | ★ 1.3M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,816,000.00 |
| Revenue This Year | N/A | $6.32 |
| Revenue Next Year | N/A | $124.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.05 |
| 52 Week Low | $4.25 | $0.37 |
| 52 Week High | $13.68 | $2.09 |
Technical Indicators
Market Signals| Indicator | CADL | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 39.40 |
| Support Level | $5.45 | $1.63 |
| Resistance Level | $6.14 | $1.77 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 16.73 | 4.08 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.